Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment.
Epidemiology
Epilepsy
Mechanisms
Pharmacoresistance
Risk factors
Treatment
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
23
05
2019
revised:
01
09
2019
accepted:
21
09
2019
pubmed:
29
9
2019
medline:
28
5
2021
entrez:
28
9
2019
Statut:
ppublish
Résumé
Understanding the natural history of and factors associated with pharmacoresistant epilepsy provides the foundation for formulating mechanistic hypotheses that can be evaluated to drive the development of novel treatments. This article reviews the modern definition of drug-resistant epilepsy, its prevalence and incidence, risk factors, hypothesized mechanisms, and the implication of recognizing pharmacoresistance in therapeutic strategies. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
Identifiants
pubmed: 31560910
pii: S0028-3908(19)30348-X
doi: 10.1016/j.neuropharm.2019.107790
pii:
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107790Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.